GB202106972D0 - Medium molecular weight heparin - Google Patents

Medium molecular weight heparin

Info

Publication number
GB202106972D0
GB202106972D0 GBGB2106972.9A GB202106972A GB202106972D0 GB 202106972 D0 GB202106972 D0 GB 202106972D0 GB 202106972 A GB202106972 A GB 202106972A GB 202106972 D0 GB202106972 D0 GB 202106972D0
Authority
GB
United Kingdom
Prior art keywords
molecular weight
weight heparin
medium molecular
medium
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2106972.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bhogal Pervinder Singh
Original Assignee
Bhogal Pervinder Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhogal Pervinder Singh filed Critical Bhogal Pervinder Singh
Priority to GBGB2106972.9A priority Critical patent/GB202106972D0/en
Publication of GB202106972D0 publication Critical patent/GB202106972D0/en
Priority to CA3219993A priority patent/CA3219993A1/en
Priority to EP22729556.5A priority patent/EP4337225A1/en
Priority to US18/290,533 priority patent/US20240245718A1/en
Priority to PCT/EP2022/063222 priority patent/WO2022238587A1/en
Priority to AU2022273186A priority patent/AU2022273186A1/en
Priority to JP2023570373A priority patent/JP2024517355A/ja
Priority to CN202280045684.XA priority patent/CN117915923A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2106972.9A 2021-05-14 2021-05-14 Medium molecular weight heparin Ceased GB202106972D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin
CA3219993A CA3219993A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy
EP22729556.5A EP4337225A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy
US18/290,533 US20240245718A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy
PCT/EP2022/063222 WO2022238587A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy
AU2022273186A AU2022273186A1 (en) 2021-05-14 2022-05-16 Medium molecular weight heparin for use in the treatment of endotheliopathy
JP2023570373A JP2024517355A (ja) 2021-05-14 2022-05-16 血管内皮炎の治療において使用するための中間分子量ヘパリン
CN202280045684.XA CN117915923A (zh) 2021-05-14 2022-05-16 用于治疗内皮病的中分子量肝素

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2106972.9A GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin

Publications (1)

Publication Number Publication Date
GB202106972D0 true GB202106972D0 (en) 2021-06-30

Family

ID=76550734

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2106972.9A Ceased GB202106972D0 (en) 2021-05-14 2021-05-14 Medium molecular weight heparin

Country Status (8)

Country Link
US (1) US20240245718A1 (enExample)
EP (1) EP4337225A1 (enExample)
JP (1) JP2024517355A (enExample)
CN (1) CN117915923A (enExample)
AU (1) AU2022273186A1 (enExample)
CA (1) CA3219993A1 (enExample)
GB (1) GB202106972D0 (enExample)
WO (1) WO2022238587A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024381335A1 (en) 2023-11-17 2026-05-21 Glycos Biomedical Ltd. Medium molecular weight heparin
GB202407360D0 (en) 2024-05-23 2024-07-10 Glycos Biomedical Ltd Functionalised medium molecular weight heparin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045532A1 (zh) * 1999-06-30 2002-11-29 Hamilton Civic Hospitals Research Development, Inc. 抑制与凝结有关凝结因子的肝素成份
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
CN113825517A (zh) * 2019-05-16 2021-12-21 艾克塞拉医疗公司 调节内皮糖萼结构的方法
WO2022016098A1 (en) * 2020-07-17 2022-01-20 Xostem Ip, Inc. Compositions and methods for treatment of inflammatory and thromboinflammatory disorders using modified exosomes

Also Published As

Publication number Publication date
CN117915923A (zh) 2024-04-19
JP2024517355A (ja) 2024-04-19
US20240245718A1 (en) 2024-07-25
EP4337225A1 (en) 2024-03-20
WO2022238587A1 (en) 2022-11-17
CA3219993A1 (en) 2022-11-17
AU2022273186A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
IL327232A (en) Next-generation molecular characterization
HUE057900T2 (hu) Ultramagas vágási ellenállású és ultramagas molekulatömegû polietilén szál és eljárás ennek elõállítására
WO2011130694A3 (en) High molecular weight zwitterion-containing polymers
PL2158233T3 (pl) Addukty, addukty i oligomery lub addukty, oligomery i polimery o małym ciężarze cząsteczkowym oraz ich wytwarzanie
WO2012169790A3 (ko) 락타이드 공중합체를 포함하는 포장용 필름
CA3290051A1 (en) Iodine-infused ultra high molecular weight polyethylene
CA209354S (en) Shelving
GB202017227D0 (en) Polymer
GB202217216D0 (en) Preparation of medium molecular weight heparin
EP4217540A4 (en) RAIL SHOCK ABSORBER SYSTEM ARRANGED CONTINUOUSLY ALONG THE RAIL
EP3568140C0 (en) Medium molecular weight heparin for use in the treatment of venous thromboembolism in cancer
GB202407360D0 (en) Functionalised medium molecular weight heparin
GB201913690D0 (en) Molecular phenotype classification
GB2604635B (en) Polymer
GB202017341D0 (en) Polymer
GB202010493D0 (en) Polymer
CA3273867A1 (en) Preparation of medium molecular weight heparin
IL317158A (en) Chemically modified heparin
GB202102396D0 (en) Molecular adjuvant
GB202008973D0 (en) Polymers
EP4288987A4 (en) MOLECULAR HYPER-CAPACITOR
GB202012237D0 (en) Mozen weight
CA204437S (en) Shelving
EM87893170010S (sk) Police [nábytok]
GB202402623D0 (en) Defined molecular weight peglation agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)